Praxis Precision Medicines, Inc. PRAX Relutrigine — Program-specific expenses
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Praxis Precision Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The official record: Praxis Precision Medicines, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Praxis Precision Medicines, Inc.'s relutrigine — program-specific expenses.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Praxis Precision Medicines, Inc.'s relutrigine — program-specific expenses?
- Praxis Precision Medicines, Inc. (PRAX) reported relutrigine — program-specific expenses of $12.85M in Q1 2026.
- How has Praxis Precision Medicines, Inc.'s relutrigine — program-specific expenses changed year-over-year?
- Praxis Precision Medicines, Inc.'s relutrigine — program-specific expenses increased by 139.1% year-over-year, from $5.38M to $12.85M.
- What is the long-term trend for Praxis Precision Medicines, Inc.'s relutrigine — program-specific expenses?
- Over 2 years (2023 to 2025), Praxis Precision Medicines, Inc.'s relutrigine — program-specific expenses has grown at a 239.1% compound annual growth rate (CAGR), from $4M to $45.95M.
- What does relutrigine — program-specific expenses mean?
- This metric represents the total direct costs and operating expenses specifically attributable to the development, manufacturing, and commercialization activities of the Relutrigine product candidate. It encompasses research and development outlays, clinical trial costs, and supply chain expenditures required to advance this specific therapeutic asset through its lifecycle. By isolating these costs, the company provides transparency into the capital intensity and resource allocation dedicated to this particular clinical program.